Overview

Management of Etonogestrel Subdermal Implant-related Bleeding

Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Petra M. Casey
Treatments:
Doxycycline
Etonogestrel